I n Australia, about 65% of men and 50% of women are exposed to a potentially traumatic event in their lifetime. Examples of traumatic events include assault and sexual assault, transport accidents, war, and natural disasters. A degree of psychological distress is common in the early aftermath of such traumatic exposure, but when distress persists and interferes with psychosocial functioning, a diagnosis of acute stress disorder (ASD) or post-traumatic stress disorder (PTSD) should be considered. Features of PTSD are shown in Box 1.

The estimated 12-month prevalence of PTSD in the Australian general population is 1.3%, representing around 200,000 cases in any one year, and the lifetime prevalence rate (the percentage of people who are diagnosed with the disorder in their lifetime) is likely to be about double this figure.1

While a diagnosis of PTSD requires that the symptoms be present for at least a month, ASD is diagnosed between 2 days and 1 month after a traumatic event. There is significant overlap in the diagnostic criteria for these conditions. The diagnoses differ in that ASD requires the experience of several dissociative symptoms not included in PTSD (such as detachment, reduced awareness of surroundings and depersonalisation), while PTSD places greater emphasis on avoidance symptoms by requiring at least three (such as avoidance of thoughts and feelings about the trauma, avoidance of activities, places or people that may act as reminders of the trauma, and passive avoidance symptoms such as emotional numbing and detachment). A growing body of evidence indicates that people with ASD are at high risk of developing PTSD.4 However, primarily because of the emphasis on dissociative symptoms, about half of people with PTSD do not meet ASD criteria in the first month after trauma.

In most patients, PTSD is unlikely to present as a stand-alone problem. Comorbid conditions, including depression, other anxiety disorders, and substance misuse, are common. Associated problems include relationship difficulties, excessive anger, and occupational impairment.

<table>
<thead>
<tr>
<th>1 Types of symptoms that characterise post-traumatic stress disorder (PTSD)*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Re-experiencing:</strong> Intrusive distressing recollections of the traumatic event; flashbacks; nightmares; intense psychological distress or physical reactions, such as sweating, heart palpitations or panic when faced with reminders of the event (one symptom required).</td>
</tr>
<tr>
<td><strong>Avoidance and emotional numbing:</strong> Avoidance of activities, places, thoughts, feelings, or conversations related to the event; restricted emotions; loss of interest in normal activities; feeling detached from others; psychogenic amnesia; sense of foreshortened future (three symptoms required).</td>
</tr>
<tr>
<td><strong>Hyperarousal:</strong> Difficulty sleeping; irritability; difficulty concentrating; hypervigilance; exaggerated startle response (two symptoms required).</td>
</tr>
</tbody>
</table>

*Symptoms must be present for at least a month before a diagnosis can be made.3

**ABSTRACT**

- General practitioners have an important role to play in helping patients after exposure to severe psychological trauma.
- In the immediate aftermath of trauma, GPs should offer “psychological first aid”, which includes monitoring of the patient’s mental state, providing general emotional support and information, and encouraging the active use of social support networks, and self-care strategies.
- Drug treatments should be avoided as a preventive intervention after traumatic exposure; they may be used cautiously in cases of extreme distress that persists.
- Adults with acute stress disorder (ASD) and post-traumatic stress disorder (PTSD) should be provided with trauma-focused cognitive behaviour therapy (CBT). Eye movement desensitisation and reprocessing (EMDR) in addition to in-vivo exposure (confronting avoided situations, people or places in a graded and systematic manner) may also be provided for PTSD.
- Drug treatments should not normally replace trauma-focused psychological therapy as a first-line treatment for adults with PTSD.
- If medication is considered for treating PTSD in adults, selective serotonin reuptake inhibitor antidepressants are the first choice. Other new generation antidepressants and older tricyclic antidepressants should be considered as second-line pharmacological options. Monoamine oxidase inhibitors may be considered by mental health specialists for use in people with treatment-resistant symptoms.

The clinical recommendations in this article are based on the recently released evidence-based Australian guidelines for the treatment of adults with acute stress disorder and posttraumatic stress disorder5 and the United Kingdom PTSD guidelines.6

**Screening and assessment in general practice**

Traumatic stress problems present to general practitioners in a variety of ways. Sometimes patients present with expressed concern about their emotional wellbeing after exposure to a traumatic stressor, and may directly report specific symptoms of ASD or PTSD. Such presentations are more common after a recent discrete trauma, such as a motor vehicle accident or an assault. Other patients may present with a greater focus on related problems, such as substance misuse, depression or a specific phobic reaction (such as fear of driving). In such cases, the link to the traumatic experience may not be explicitly made. However, commonly, patients with traumatic stress problems present to GPs with general health complaints, including headaches, gastrointestinal...
Management immediately after trauma

Most people experience some level of distress after a traumatic event, and recover by using their own resources, including their natural coping strategies and social support networks. Thus, formal intervention during the first couple of weeks is not recommended as a routine option, and help should normally be limited to practical and emotional support tailored to individual needs. Recommendations for GPs managing patients in the immediate aftermath of trauma are described in Box 3.

Managing ASD and PTSD

In patients whose distress is persistent or severe enough to cause significant impairment, a diagnosis of ASD or PTSD should be considered. Thorough clinical assessment should be conducted, including physical, psychological, social, and occupational functioning, as well as assessment of the risk of self-harm, suicide and harm to others. An interview with a family member or friend can be very helpful as part of the assessment process.

PTSD is only one of the potential mental health outcomes after trauma. Thus, assessment should consider other conditions such as depression, other anxiety disorders, and substance misuse, along with the implications for treatment.

A useful self-report measure for assessing PTSD (both initially and to monitor progress throughout treatment) is the PTSD checklist, described in Box 4.

Treatment for PTSD

The findings of over 58 well controlled psychological and pharmacological treatment studies are reviewed in the Australian guidelines. Implications from these findings are summarised below.

• Adults with PTSD should receive trauma-focused psychological interventions from appropriately trained mental health practitioners. These interventions will usually take the form of cognitive behaviour therapy (CBT), or eye movement desensitisation and reprocessing (EMDR) in addition to confronting avoided situations, people or places in a graded and systematic manner (in-vivo exposure).

• Key elements of trauma-focused psychological treatment include:
  - confronting the traumatic memory in a controlled and safe environment (imaginal exposure);
  - identifying, challenging and modifying biased or distorted thoughts and interpretations about the event and its meaning (cognitive therapy); and
  - in-vivo exposure.

Information for general practitioners managing patients in the immediate aftermath of trauma

• “Psychological first aid” should be undertaken. This involves ongoing monitoring of the patient’s mental state, providing general emotional support, ensuring the patient’s safety and security, providing practical assistance and information, and encouraging active use of social support mechanisms and self-care strategies.

• Structured interventions (such as psychological debriefing, with a focus on recounting the traumatic event and ventilation of feelings) should not be offered on a routine basis. However, patients who wish to discuss the experience, and who show a capacity to tolerate the associated distress, should be supported in doing so. The GP should keep in mind the potential adverse effects of excessive ventilation in those who are very distressed or have dissociative symptoms.

• Drug treatments should not be used as a preventive intervention after exposure to trauma (although they may be used cautiously in cases of extreme distress that does not settle, or of severe insomnia).
In the context of comorbidity:

Drug treatments for PTSD should not normally be used in preference to trauma-focused psychological therapy as a routine first-line treatment for adults, either by GPs or by specialist mental health professionals. However, antidepressant medication may be considered for the treatment of PTSD in adults if the patient:

- is unwilling or unable to engage in trauma-focused psychological treatment;
- is not in a sufficiently stable condition to commence trauma-focused psychological treatment;
- has not gained significant benefit from a trial of trauma-focused psychological treatment; or
- is experiencing severe dissociative symptoms that are likely to be exacerbated by trauma-focused therapy.

Where medication is considered for treating PTSD in adults, selective serotonin reuptake inhibitor (SSRI) antidepressants should be the first choice for both GPs and mental health specialists. Although sertraline is the most studied of the SSRIs in PTSD, it is hard to argue for the superior efficacy of one SSRI over another.

Other new generation antidepressants (notably mirtazapine) and the older tricyclic antidepressants should be considered as a second-line pharmacological option. Monoamine oxidase inhibitors may be considered for use by mental health specialists for people with treatment-resistant symptoms.

When an adult with PTSD has responded to drug treatment, it should be continued for at least 12 months before gradual withdrawal.

Pharmacological interventions should be considered as an adjunct to psychological treatment where core PTSD or comorbid symptoms are of sufficient severity to impede benefit from psychological treatment alone.

In the context of comorbidity:

- When PTSD is comorbid with depression, in most cases, the PTSD should be treated first, as depression will often ameliorate as PTSD symptoms reduce. However, when depressive symptoms prevent effective engagement in treatment or are associated with a high risk of suicide, the depression should be managed first.
- When PTSD is comorbid with substance misuse disorders, in patients whose level of substance misuse is low-risk to medium-risk, treat both conditions simultaneously, as the two are likely to interact to maintain each other. Treatment may be less effective if either the PTSD or the substance misuse remains untreated. Substance misuse should be managed before proceeding to the trauma-focused components of PTSD treatment.

Treatment for ASD

If significant symptoms have been present for more than 2 days but less than a month after trauma, a diagnosis of ASD should be considered. Compared with the large number of treatment studies of PTSD, there have been only a small number of high-quality studies into the psychological and pharmacological treatment of ASD. If ASD is diagnosed, the patient should be offered individual trauma-focused CBT, including exposure and/or cognitive therapy. This treatment should not start until 2 weeks after the traumatic event. Drug treatments should not be used within 4 weeks of symptoms appearing unless the severity of the person’s distress cannot be managed by psychological means alone.

When and why to refer

GPs can do much to assist people recovering from trauma. Reassurance and support, simple information, and advice on self-care will often be enough to facilitate a natural recovery process. However, if the person’s symptoms are severe, and associated with high levels of prolonged distress, or interfere in social and occupational functioning, referral to a mental health care provider (such as a psychiatrist or clinical psychologist) is advisable. Helping the patient to understand what to expect is an important component of referral for specialist care. Trauma-focused psychological treatment (CBT, or EMDR plus in-vivo exposure) can be expected to reduce the symptoms of PTSD, relieve anxiety and depression, and improve quality of life. These therapies can also be effective for people who have experienced prolonged or repeated traumatic events, although more time to establish a trusting therapeutic alliance, more attention to teaching emotional regulation skills, and a gradual approach to exposure therapy may be required in such cases. Interventions that focus purely on reducing symptoms (such as anxiety management), although not as effective when used on their own, are useful adjuncts to trauma-focused treatment. Non-trauma-focused interventions, such as supportive counselling, should not normally be provided to adults with PTSD. Specialist pharmacological treatment for PTSD is best managed by an appropriately experienced psychiatrist, although the continued involvement of patients’ GPs in the process is strongly recommended.

Unfortunately, research indicates that only a minority of practitioners apply evidence-based treatments for PTSD in their routine clinical care. 13 Thus, when referring patients for specialist psychological or pharmacological treatment, it would be prudent to consider whether the specialist practitioner has expertise in evidence-based trauma interventions.

Acknowledgements

We thank Dr Adele Weston from Health Technology Analysts for support and assistance in the guideline development project in her role as Guideline Assessment Registrar consultant. We also thank the staff of the Australian Centre for Posttraumatic Mental Health for their assistance with this project.

Competing interests

None identified.
Author details

David Forbes, MClinPsychol, PhD, Associate Professor1
Mark C Creamer, PhD, Professor1
Andrea J Phelps, MPsych, Senior Lecturer1
Anne-Laure Couineau, MA, Senior Lecturer1
John A Cooper, MPM, Senior Lecturer1
Richard A Bryant, PhD, Professor2
Alexander C McFarlane, MD, Professor3
Grant J Devilly, PhD, Professorial Fellow4
Lyndal R Matthews, PhD, Senior Lecturer5
Beverley Raphael, MD, Professor6

1 Australian Centre for Posttraumatic Mental Health, University of Melbourne, Melbourne, VIC.
2 School of Psychology, University of New South Wales, Sydney, NSW.
3 Centre for Military and Veterans’ Health, University of Adelaide, Adelaide, SA.
4 Brain Sciences Institute, Swinburne University, Melbourne, VIC.
5 Behavioural and Community Health Sciences, University of Sydney, Sydney, NSW.
6 Centre for Disasters and Terrorism, University of Western Sydney, Sydney, NSW.

Correspondence: dforbes@unimelb.edu.au

References